IGF-1R inhibition induces MEK phosphorylation to promote survival in colon carcinomas

4 views | Apr 07 2021

Qing Wang et al. found that the treatment of colon tumor cells with IGF-1R inhibitors stimulated p70S6K1 activity via MEK1/2 to promote survival, providing a new strategy for colorectal cancer therapeutics. [Read the Full Post]

Cardiomyocyte protective effects of thyroid hormone during hypoxia/reoxygenation injury through activating of IGF-1-mediated PI3K/Akt signalling

5 views | Mar 31 2021

Bin Zeng et al. showed that T3 pretreatment protected cardiomyocytes against H/R-induced injury by activating the IGF-1-mediated PI3K/Akt signalling pathway. [Read the Full Post]

Depletion of insulin-like growth factor 1 receptor increases radiosensitivity in colorectal cancer

6 views | Mar 21 2021

Yi Li et al. supported the notion that the radiosensitivity of radiation-resistant colorectal cancer cells could be enhanced by directly targeting IGF1R expression or activity. [Read the Full Post]

Hsp90 Inhibitor; NVP-AUY922 in Combination with Doxorubicin Induces Apoptosis and Downregulates VEGF in MCF-7 Breast Cancer Cell Line

35 views | Oct 16 2020

Mahshid Mohammadian et al. indicated an effective action of NVP-AUY922 in combined with DOX in this cell line. [Read the Full Post]

Heat Shock Protein 90 (Hsp90)-Inhibitor-Luminespib-Loaded-Protein-Based Nanoformulation for Cancer Therapy

39 views | Oct 15 2020

Ankit K Rochani et al.suggested that DNP-based aqueous nanoformulations could be used in both pancreatic (MIA PaCa-2) and breast (MCF-7) cancer therapy. [Read the Full Post]

Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors

82 views | Aug 23 2020

Abhay Singh et al. provided a summary of the clinical development of crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib and highlighted current management paradigms, current and evolving clinical information, emerging clinical decision-making and sequencing of therapy in advanced, metastatic, or recurrent ALK-positive NSCLC. [Read the Full Post]

Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer

93 views | Aug 04 2020

Kyoung-Ho Pyo et al. found that ALK-positive tumors progressing on ceritinib was not immunogenic enough to respond to immune checkpoint inhibitors. [Read the Full Post]

IGF-1/IGF-1R/FAK/YAP Transduction Signaling Prompts Growth Effects in Triple-Negative Breast Cancer (TNBC) Cells

71 views | Jul 20 2020

Damiano Cosimo Rigiracciolo et al. suggested that the IGF-1/IGF-1R/FAK/YAP axis might contribute to the progression of the aggressive TNBC subtype. [Read the Full Post]

Critical role of SOX2-IGF2 signaling in aggressiveness of bladder cancer

65 views | Jul 20 2020

Yu-Fan Chiu et al. indicated the SOX2-IGF2 signaling affected the aggressiveness of bladder cancer cell growth. [Read the Full Post]

Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor

219 views | Sep 29 2019

Mulvihill MJ et al. showed that OSI-906 is a novel, potent, selective and orally bioavailable dual IGF-1R/IR kinase inhibitor with favorable preclinical drug-like properties, which has demonstrated in vivo efficacy in tumor models and is currently in clinical testing. [Read the Full Post]